Humacyte launches Phase II vascular trauma Humacyl vessel trial

Humacyte said yesterday it launched a U.S. Phase II trial of its Humacyl investigational human acellular vessel exploring the systems’ use for vascular replacement or reconstruction in patients with life or limb-threatening vascular trauma. The Research Triangle Park, N.C.-based company said it hopes to enroll 40 adult patients at six U.S. sites for the trial, with patient monitoring extending out to 24 months. “As a world leader in trauma research, we are constantly exploring new and innovative approaches to treating life threatening injuries. We look forward to evaluating this bioengineered blood vessel in the treatment of appropriate patients requiring vascular surgical repair,” Dr. Thomas Scalea of the University of Maryland’s R Adams Cowley Shock Trauma Center said in a prepared release. The first patient in the trial was enrolled last month at Newark, N.J.’s Rutgers University Hospital, Humacyte said. The company is hopeful that it will have topline patient data from the study by late 2020. “A tremendous medical need exists for patients with traumatic injuries who are in need of vascular reconstruction both in the civilian and military populations. Advancements in tissue engineering, such as Humacyte’s bioengineered vessel, have the potential to be a game-changer for both patients and the brave members of our armed forces who may experience this critical need. Rutgers University is thrilled to participate in this significant investi...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Featured Vascular Humacyte Source Type: news